Drug Trial Radar · NCT07199257
A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.
Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Sep 25, 2025
Primary completion
May 15, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies.
Conditions
- Allergic Rhinitis, Seasonal
Interventions
GR1802 injectionBiological
Recombinant fully human anti-IL4Rα monoclonal antibody drug.
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)(Part One)Time frame: up to 12 weeks
- Change from Baseline in rTNSS( reflective total nasal symptom scores)(Part Two)Time frame: up to 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongnan Hospital of Wuhan university
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.